The ventures arm of Channel 4, the state-owned broadcaster, is taking a stake in a brand new digital well being firm which goals to assist deal with the rising scourge of persistent allergy symptoms within the UK.
The so-called media-for-equity association will give the AllergyRhino model publicity utilizing Channel 4’s promoting stock because it seeks to construct title recognition.
It’s the newest such settlement signed by Channel 4 Ventures, with earlier counterparties having included the web property agent Purplebricks and Crowdcube, the crowd-funding platform.
Cash newest: Tax warning over state pension
AllergyRhino is chaired by Dr Sneh Khemka, a former international medical chief at Bupa and ex-chief government of Simplyhealth.
It counts Professor Adam Fox, previous president of the British Society for Allergy and Scientific Immunology, and Professor Stephen Until, a advisor allergist at Man’s and St Thomas’ NHS Basis Belief, among the many members of its scientific advisory staff.
The corporate’s formation comes as the issue of persistent allergy symptoms soars in Britain, with knowledge suggesting that one in 4 individuals now reside with seasonal or persistent rhinitis, triggered by components corresponding to hay fever and dirt mite allergy.
It’s stated to be the fastest-growing persistent situation amongst youngsters.
Its funding spherical – encompassing the worth of the Channel 4 Ventures deal and capital from Lexham – is claimed to be value greater than £4m.
Channel 4 declined to remark, whereas neither Allergy Rhino nor Lexham may very well be reached for remark.
